Arcus Biosciences, Inc. (RCUS) vs Tarsus Pharmaceuticals, Inc. (TARS)

Arcus Biosciences, Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Tarsus Pharmaceuticals, Inc. is the larger, with a market value of $3.6B against $3.2B — 1.1× the size. Tarsus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 105.2% against −55.3%. Tarsus Pharmaceuticals, Inc. has the higher net margin (−7.67% vs −393.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Tarsus Pharmaceuticals, Inc. leads on 12 and Arcus Biosciences, Inc. on 4.

Valuation

Metric RCUS TARS Biotechnology median
P/E n/m n/m 7.88
P/S 26.65 5.42 11.47
P/B 6.72 9.47 2.52
Price to free cash flow n/m 69.88 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 21.52 4.80 10.73
Earnings yield (15.77%) (1.44%) (28.84%)
Free cash flow yield (15.26%) 1.43% (23.03%)

Profitability

Metric RCUS TARS Biotechnology median
Gross margin 100.00% 93.28% 65.16%
Operating margin (415.38%) (8.00%) 0.00%
Net margin (393.16%) (7.67%) 0.00%
Free cash flow margin (405.13%) 9.24% 0.00%
Return on equity (90.82%) (13.68%) (57.72%)
Return on assets (46.02%) (8.40%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RCUS TARS Biotechnology median
Revenue growth (TTM) (55.34%) 105.17% 5.64%
EPS growth (last fiscal year) (4.78%) 48.21% —
Revenue growth, 5-year CAGR 25.93% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RCUS TARS Biotechnology median
Debt to equity 0.22 0.21 0.00
Current ratio 3.82 3.20 4.73
Net debt to EBITDA 2.27 4.66 0.96

Dividend

Metric RCUS TARS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric RCUS TARS Biotechnology median
Market cap 3.19b 3.55b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack